Switch theme
Sign up to access all valuation multiples
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
2001
17K+
LTM Revenue $7.9B
LTM EBITDA $2.7B
$24.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Zimmer Biomet has a last 12-month revenue (LTM) of $7.9B and a last 12-month EBITDA of $2.7B.
In the most recent fiscal year, Zimmer Biomet achieved revenue of $7.7B and an EBITDA of $2.3B.
Zimmer Biomet expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zimmer Biomet valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $7.9B | XXX | $7.7B | XXX | XXX | XXX |
| Gross Profit | $5.6B | XXX | $5.5B | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | $2.7B | XXX | $2.3B | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 29% | XXX | XXX | XXX |
| EBIT | $2.2B | XXX | $1.5B | XXX | XXX | XXX |
| EBIT Margin | 28% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $1.6B | XXX | $904M | XXX | XXX | XXX |
| Net Margin | 20% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $5.7B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Zimmer Biomet's stock price is $92.
Zimmer Biomet has current market cap of $18.2B, and EV of $24.0B.
See Zimmer Biomet trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $24.0B | $18.2B | XXX | XXX | XXX | XXX | $7.99 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Zimmer Biomet has market cap of $18.2B and EV of $24.0B.
Zimmer Biomet's trades at 3.1x EV/Revenue multiple, and 10.7x EV/EBITDA.
Equity research analysts estimate Zimmer Biomet's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zimmer Biomet has a P/E ratio of 11.3x.
See valuation multiples for Zimmer Biomet and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $18.2B | XXX | $18.2B | XXX | XXX | XXX |
| EV (current) | $24.0B | XXX | $24.0B | XXX | XXX | XXX |
| EV/Revenue | 3.0x | XXX | 3.1x | XXX | XXX | XXX |
| EV/EBITDA | 9.0x | XXX | 10.7x | XXX | XXX | XXX |
| EV/EBIT | 10.9x | XXX | 15.7x | XXX | XXX | XXX |
| EV/Gross Profit | 4.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 11.3x | XXX | 20.2x | XXX | XXX | XXX |
| EV/FCF | 22.9x | XXX | 21.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialZimmer Biomet's last 12 month revenue growth is 6%
Zimmer Biomet's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Zimmer Biomet's rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zimmer Biomet's rule of X is 49% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Zimmer Biomet and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | 10% | XXX | XXX | XXX |
| Rule of 40 | 36% | XXX | 35% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 49% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zimmer Biomet acquired XXX companies to date.
Last acquisition by Zimmer Biomet was XXXXXXXX, XXXXX XXXXX XXXXXX . Zimmer Biomet acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Zimmer Biomet founded? | Zimmer Biomet was founded in 2001. |
| Where is Zimmer Biomet headquartered? | Zimmer Biomet is headquartered in United States of America. |
| How many employees does Zimmer Biomet have? | As of today, Zimmer Biomet has 17K+ employees. |
| Who is the CEO of Zimmer Biomet? | Zimmer Biomet's CEO is Mr. Ivan Tornos. |
| Is Zimmer Biomet publicy listed? | Yes, Zimmer Biomet is a public company listed on NYS. |
| What is the stock symbol of Zimmer Biomet? | Zimmer Biomet trades under ZBH ticker. |
| When did Zimmer Biomet go public? | Zimmer Biomet went public in 2001. |
| Who are competitors of Zimmer Biomet? | Similar companies to Zimmer Biomet include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Zimmer Biomet? | Zimmer Biomet's current market cap is $18.2B |
| What is the current revenue of Zimmer Biomet? | Zimmer Biomet's last 12 months revenue is $7.9B. |
| What is the current revenue growth of Zimmer Biomet? | Zimmer Biomet revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Zimmer Biomet? | Current revenue multiple of Zimmer Biomet is 3.0x. |
| Is Zimmer Biomet profitable? | Yes, Zimmer Biomet is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Zimmer Biomet? | Zimmer Biomet's last 12 months EBITDA is $2.7B. |
| What is Zimmer Biomet's EBITDA margin? | Zimmer Biomet's last 12 months EBITDA margin is 34%. |
| What is the current EV/EBITDA multiple of Zimmer Biomet? | Current EBITDA multiple of Zimmer Biomet is 9.0x. |
| What is the current FCF of Zimmer Biomet? | Zimmer Biomet's last 12 months FCF is $1.1B. |
| What is Zimmer Biomet's FCF margin? | Zimmer Biomet's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of Zimmer Biomet? | Current FCF multiple of Zimmer Biomet is 22.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
